iBio to Present at the UBS Global Healthcare Virtual Conference
iBio, a biotech innovator and biologics contract manufacturer, will present a business update at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 4:00 p.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iBio, a biotech innovator and biologics contract manufacturer, will present a business update at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 4:00 p.m. Eastern Time. This presentation underscores iBio's commitment to advancing its plant-based biologics manufacturing, particularly through its FastPharming® System, which enables rapid delivery of monoclonal antibodies and vaccines. The event will be webcast live and available for later viewing on iBio's website under the Investors section.
Details
News Market Reaction – IBIO
The recorded move for IBIO in the trading session of this news was +4.38%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRYAN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that management will present an update on the Company’s business at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 4:00 p.m Eastern Time.
The presentation will be webcast live and archived on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section.
About iBio, Inc.
iBio is a global leader in plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary products on the FastPharming Platform, which include biopharmaceuticals for the treatment of fibrotic and infectious diseases, amongst others. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services, including Glycaneering™ Development Services for advanced recombinant protein design. For more information, visit www.ibioinc.com.
Contact:
Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.